Marketwire - Pharmaceuticals and Biotech

Adaltis Inc. obtient une ordonnance de la Cour lui conf�rant la protection contre ses cr�anciers

Fri, 03 Jul 2009 15:51:00 EDT

MONTREAL, QUEBEC--(Marketwire - 3 juillet 2009) - A la suite de la publication ce matin d'un communiqu� et d'une proc�dure subs�quente devant la Cour sup�rieure du Qu�bec, Adaltis Inc. (TSX:ADS), soci�t� internationale de tests diagnostiques in vitro, a annonc� aujourd'hui qu'elle a obtenu une ordonnance lui conf�rant la protection contre ses cr�anciers aux termes de la Loi sur les arrangements avec les cr�anciers des compagnies (Canada) (la "LACC"). Par ailleurs, la Cour sup�rieure du Qu�bec a approuv� la convention de financement du d�biteur-exploitant conclue avec Entreprises Victoria Square Inc. relativement � un nouveau financement d'un montant pouvant atteindre 3 millions de dollars, laquelle convention avait �t� annonc�e ant�rieurement. Le produit du financement servira � financer les activit�s de la soci�t� pendant qu'elle se restructure sous la protection de la Cour au Canada.

Adaltis Inc. Obtains Court Order for Creditor Protection

Fri, 03 Jul 2009 15:50:00 EDT

MONTREAL, QUEBEC--(Marketwire - July 3, 2009) - Further to a news release issued this morning and the completion of subsequent proceedings before the Quebec Superior Court, Adaltis Inc. (TSX:ADS), an international in vitro diagnostic (IVD) company, today announced that it has obtained an Order for creditor protection under the Companies' Creditors Arrangement Act (Canada). The Quebec Superior Court also approved the previously announced Debtor-in-Possession (DIP) financing arrangement with Victoria Square Ventures Inc. for new financing in an amount of up to $3 million. The proceeds of the financing will be used to fund the Corporation's operations as it reorganizes under the protection of the Court in Canada.

ALDA Pharmaceuticals to Undertake Non-Brokered Private Placement

Fri, 03 Jul 2009 14:59:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 3, 2009) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) (the "Company") announces that it is undertaking a non-brokered private placement of up to 3 million units of the Company (the "Units") at a price of $0.20 per Unit for proceeds to the Company of up to $600,000. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.40 per common share for a period of twelve (12) months from the date of the issuance of the purchase warrant with a forced exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.80 then the exercise period of the warrants will be reduced to a period of 10 days following such tradi

Imaging3 to Host "State of the Company" Conference Call

Fri, 03 Jul 2009 07:00:00 EDT

BURBANK, CA--(Marketwire - July 3, 2009) - Imaging3T, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Monday, July 6, 2009 at 11:00am PDT, the company's CEO, Mr. Dean Janes, will be hosting a conference call to provide an update on the company's plans as well as an update on FDA approval progress.

Addex to Host R&D Day on July 16

Fri, 03 Jul 2009 06:17:00 EDT

GENEVA, SWITZERLAND--(Marketwire - July 3, 2009) - Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) invites investors, analysts, media and other interested parties to attend its annual R&D day on Thursday, July 16, 2009 in Geneva, Switzerland.

Addex management will discuss advances made with its small molecule allosteric modulator drug discovery platform as well as the status of multiple drug candidates, including the clinical-stage products ADX10059, ADX48621 and ADX71149, which are in development for gastroesophageal reflux disease (GERD), migraine prevention, Parkinson's disease, schizophrenia and anxiety. Addex also will disclose new early stage programs for important indications in metabolic disease and inflammation.

Addex to Host R&D Day on July 16

Fri, 03 Jul 2009 06:00:00 EDT

PLAN-LES-OUATES GENEVA, SWITZERLAND--(Marketwire - July 3, 2009) -

Geneva, Switzerland, 2 July 2009 - Allosteric modulation company Addex Pharmaceuticals (SIX: ADXN) invites investors, analysts, media and other interested parties to attend its annual R&D day on Thursday, July 16, 2009 in Geneva, Switzerland. Addex management will discuss advances made with its small molecule allosteric modulator drug discovery platform as well as the status of multiple drug candidates, including the clinical-stage products ADX10059, ADX48621 and ADX71149, which are in development for gastroesophageal reflux disease (GERD), migraine prevention, Parkinson's disease, schizophrenia and anxiety. Addex also will disclose new early stage programs for important indications in metabolic disease and inflammation.

HearAtLast to Develop 25 New Hearing Store Locations in the USA and Canada

Thu, 02 Jul 2009 21:54:00 EDT

MISSISSAUGA, ON--(Marketwire - July 2, 2009) - HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced today it will be developing 25 new Hearing Store locations in various markets in the USA and Canada. These new locations will be by way of a joint venture agreement between certain Joint Venture Partners and HearAtLast Holdings, Inc.

Declare Your Independence and Stop Smoking for Good This Fourth of July

Thu, 02 Jul 2009 19:12:00 EDT

LA County Residents Can Visit Their Local Ralphs Pharmacy for Free Nicotine Patches or Gum, While Supplies Last

Stem Cell Therapeutics Corp. Announces Early Exercise Warrant Incentive Program

Thu, 02 Jul 2009 18:00:00 EDT

CALGARY, ALBERTA--(Marketwire - July 2, 2009) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) is pleased to announce an early warrant exercise incentive program (the "Program") designed to encourage the early exercise of up to 17,250,000 outstanding share purchase warrants (the "Warrants") for gross proceeds of up to $2,760,000. The Program will be open for a 30 day period which is anticipated to commence on July 8, 2009, and end on August 7, 2009 (the "Early Warrant Exercise Period"), subject to the approval of the TSX Venture Exchange ("TSXV"). Holders of Warrants may exercise their Warrants at a discounted price of $0.16 per Warrant during the Early Warrant Exercise Period. Prior to and following the early Warrant Exercise Period, the outstanding Warrants are exercisable to acquire common shares of the Company at a price of $0.50 per share.

ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX

Thu, 02 Jul 2009 16:35:00 EDT

GHENT, BELGIUM--(Marketwire - July 2, 2009) - Ablynx (Euronext Brussels: ABLX), a pioneer in the discovery and development of Nanobodies�, a novel class of antibody-derived therapeutic proteins, announced today its promotion to the Belgian Mid-Cap Index (Bel Mid Index or BELMID) from 1 July 2009.

The entry of Ablynx to the Bel Mid Index is dependent upon Ablynx's market capitalization, free float and velocity.

Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx commented: "The promotion of Ablynx to the Bel Mid Index is a testament to the considerable progress Ablynx has made since our IPO. We have a strong cash position and the financial turmoil over the last year has not directly negatively affected Ablynx. We continue to build and diversify our shareholder base, both domestically and internationally. There are now three Nanobodies� in clinical development and our lead programme, ALX-0081, a

Avis d'appel conf�rence de Thallion Pharmaceutiques Inc. : R�sultats du deuxi�me trimestre de 2009

Thu, 02 Jul 2009 14:27:00 EDT

Les r�sultats financiers du deuxi�me trimestre seront divulgu�s le 9 juillet 2009

Notice of Thallion Pharmaceuticals 2009 Second Quarter Conference Call

Thu, 02 Jul 2009 14:26:00 EDT

Second quarter financial results to be released on July 9, 2009

CNS Response Files Action Against Its Former CEO

Thu, 02 Jul 2009 14:22:00 EDT

COSTA MESA, CA--(Marketwire - July 2, 2009) - CNS Response, Inc. (OTCBB: CNSO) today announced that it has filed an action in the United States District Court for the Central District of California against Len Brandt, the Company's former CEO, who was terminated on April 10, 2009, and certain others. In the action, captioned CNS Response, Inc. v. Leonard Brandt, EAC Investment LP and EAC Investment, Inc., CNS Response alleges that Mr. Brandt and the other defendants have violated federal securities laws in connection with their solicitation of proxies and written consents and attempts to call and hold a special meeting in lieu of the annual meeting of stockholders.

SRS Applauds CCHIT for Listening to the Voice of the Physician

Thu, 02 Jul 2009 13:29:00 EDT

Making "Meaningful Use" Attainable Will Increase Adoption

International Drug & Explosives Detection Firm IDenta Corp. Releases Update on Marketing Trip

Thu, 02 Jul 2009 12:39:00 EDT

JERUSALEM--(Marketwire - July 2, 2009) - IDenta Corp. (PINKSHEETS: IDTA) today released an update of the recent marketing trip.

CEO Yaacov Shoham states, "All of the scheduled meetings in the US and France have been held and the results were very successful. The meetings were well organized and involved a lot of important decision makers. This was by far the most important business trip since we started our worldwide marketing program. Everyone who has seen a demonstration of the Identa's different kits, including the new General Drug Screening Kit, has been very impressed."

REMINDER: Webcast Double Feature Showcases Treatment Options at NewYork-Presbyterian Hospital for Patients With Aortic Aneurysms

Thu, 02 Jul 2009 10:30:00 EDT

ORLive Invites Vascular Surgeons, Cardiothoracic Surgeons, Interventional Cardiologists, Interventional Radiologists, Cardiologists, Primary Care Physicians, Patients and Care Seekers to Its First-Ever Back-to-Back Live Interactive Webcast on Wednesday, June 24, at 7:00PM

Demonstrations and Discussions of Continuum of Care for Aortic Aneurysms and Dissections Featuring Endovascular Approach Using Investigational "Fenestrated" Endograft and Open Surgery

Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer

Thu, 02 Jul 2009 10:29:00 EDT

LONDON, ONTARIO--(Marketwire - July 2, 2009) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from combination agent animal experiments carried out at a prominent American cancer research facility. The results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional single agent therapy for the treatment of ovarian cancer: - Tumor growth inhibition was significantly greater in the COTI-2 plus Doxil treated animals compared to the Doxil control group treated animals with:

Extensive and Rapid Diagnostic Assay for Herpesviral Infections in the Central Nervous System

Thu, 02 Jul 2009 10:16:00 EDT

HELSINKI, FINLAND--(Marketwire - July 2, 2009) -

Mobidiag's CE-IVD-marked Prove-itT Herpes-test helps the clinician in targeting antiviral treatment correctly for patients with severe herpesviral infections

Helsinki, Finland - June 2, 2009 - Finnish biotech company Mobidiag announces CE-marked herpesvirus microarray for rapid In Vitro Diagnostics (IVD) of life-threatening central nervous system infections. The achieved certificate ensures the safety of the product in clinical use and opens European markets for the company. Prove-itT Herpes identifies seven herpesviruses in a single assay, whereas most current methods search for only one virus at a time, or are unable to identify all viruses covered by Mobidiag's assay.

R&D Logic's Unique Products and Services Offering Gaining Momentum With Leading Life Sciences Companies

Thu, 02 Jul 2009 10:00:00 EDT

Preferred Provider Attracts Industry Leaders With Innovative, Cost-Effective Business Management Solution

GENEART Again Honored with "BAVARIA'S BEST 50" Award

Thu, 02 Jul 2009 09:25:00 EDT

REGENSBURG, GERMANY--(Marketwire - July 2, 2009) -

  * GENEART is among the 50 most dynamic companies in Bavaria
  * GENEART was awarded "BAVARIA'S BEST 50" by the Bavarian State
    Ministry for the third time
  * The Group's net sales increased by an average of 58 % over the
    past four years

Regensburg, July 2, 2009 - GENEART AG is among the 50 most dynamic companies in Bavaria and has been awarded "BAVARIA'S BEST 50" by the Bavarian State Ministry for the third time. Since its market entry in 2000, GENEART evolved to the world market leader in synthetic gene production. Furthermore, GENEART today is one of the leading experts worldwide in the area of Synthetic Biology.

MMR Information Systems Announces July 14 Investor Call

Thu, 02 Jul 2009 08:50:00 EDT

LOS ANGELES, CA--(Marketwire - July 2, 2009) - MMR Information Systems, Inc. (OTCBB: MMRF) (the "Company"), which through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ( "MMR") provides consumer-controlled Personal Health Records ("PHRs") (www.mymedicalrecords.com) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), announced today that it has scheduled an Investor Call on Tuesday, July 14, at 11:30 a.m. Pacific Time (U.S. and Canada).

Non-Toxic Pain Reliever Offers Safe Alternative to Harmful Painkillers

Thu, 02 Jul 2009 08:41:00 EDT

FDA Issues Warnings to Pull Vicodin and Percocet; FDA Increases Warnings for Acetaminophen and NSAIDs; StayActiv(R) Delivers Pain Relief Without Dangerous Side Effects

Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial

Thu, 02 Jul 2009 08:30:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 2, 2009) - Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP. ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a treatment for patients with elevated low-density lipoprotein (LDL) cholesterol, or "bad" cholesterol, who are not well served by current therapy. ApoB SNALP is designed to reduce the production of apolipoprotein B (ApoB), a protein produced in the liver that plays a central role in cholesterol metabolism.

Genome Canada Appoints New Chair of the Board

Thu, 02 Jul 2009 08:00:00 EDT

OTTAWA, ONTARIO--(Marketwire - July 2, 2009) - Genome Canada is pleased to announce the appointment of Dr. C. Thomas Caskey as Chair of the Board of Directors, effective June 18, 2009. Dr. Caskey has been a member of Genome Canada's Board of Directors for a number of years and has served in various capacities on a number of committees. He was appointed Vice-Chair in 2008. Dr. Caskey currently serves as Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, a research institute that seeks to investigate the cause of human diseases at the cellular and molecular levels using DNA and protein technologies to elucidate disease mechanisms. He is also professor at The Institute of Molecular Medicine, University of Texas Health Sciences Center, in Houston. Previously, he was the Managing Director of Cogene Biotech Ventures, venture capital funds designed to support early-stage biotechnology and life sciences companies. He has also served as Chairman

Nomination d'un nouveau pr�sident au conseil d'administration de G�nome Canada

Thu, 02 Jul 2009 08:00:00 EDT

OTTAWA, ONTARIO--(Marketwire - 2 juillet 2009) - G�nome Canada est heureuse d'annoncer la nomination du Dr C. Thomas Caskey au poste de pr�sident du conseil d'administration, le 18 juin 2009. Dr Caskey fait partie du conseil d'administration de G�nome Canada depuis un bon nombre d'ann�es et il a exerc� diff�rentes fonctions dans divers comit�s. Il a �t� nomm� vice-pr�sident en 2008. Dr Caskey est actuellement administrateur et chef de la direction du Brown Foundation Institute of Molecular Medicine, institut de recherche dont les travaux sont ax�s sur les causes des maladies humaines � l'�chelle cellulaire et mol�culaire et qui utilise des technologies li�es � l'ADN et aux prot�ines pour �lucider les m�canismes des maladies. Il est �galement professeur � l'Institute of Molecular Medicine du Health Sciences Center de l'Universit� du Texas � Houston. Il a auparavant exerc� les fonctions de directeur g�n�ral de Cogene Biotech Ventures, fonds de capital-risque qui vient en aide aux jeun

CNS Response Provides Third Quarter Corporate Update

Thu, 02 Jul 2009 08:00:00 EDT

Annual Meeting of Stockholders to Be Held September 2009

BioExx Awards Stock Options

Thu, 02 Jul 2009 07:00:00 EDT

Officers' Options will not Vest until Protein Isolates are Shipped

Medical Marijuana, Inc. Signs the First Cannabis Collective in Venice, California to Use Tax Remittance Card

Thu, 02 Jul 2009 04:20:00 EDT

MARINA DEL REY, CA--(Marketwire - July 2, 2009) - Medical Marijuana, Inc. (PINKSHEETS: MJNA) expands into Venice, California by signing "99 High Art Collective," which will begin to implement Medical Marijuana, Inc.'s tax remittance card in 4th quarter 2009. "The high energy marketing efforts of our Agents are building major momentum, moving us full steam ahead, as we now have 13 Cannabis Collectives who have agreed to use our Tax Remittance Card," says Rob Griffin, Chief Operations Officer of Medical Marijuana, Inc.

Russian Academy of Science Selects Zecotek Lasers for New Areas of Research

Thu, 02 Jul 2009 03:00:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 2, 2009) - Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that its proprietary Green Fiber Laser GFL 550 has been selected by the Russian Academy of Sciences (Novosibirsk) as the main laser source for Raman spectrometers in solid-state research and for confocal microscopy in biomedical (DNA) research. The lasers will also be used in a program of biomedical research for the development of new tools for confocal microscopy and flow cytometry.

MorphoSys and the University of Melbourne File New Patent Applications in MOR103 Program

Thu, 02 Jul 2009 01:36:00 EDT

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - July 2, 2009) -

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and the University of Melbourne announced today an agreement to cooperate on investigating new therapeutic applications for MorphoSys's MOR103 program. MOR103, a HuCAL antibody against human GM-CSF (Granulocyte macrophage-colony stimulating factor), is currently in development for the treatment of rheumatoid arthritis (RA). The collaboration announced today will focus on new therapeutic areas in which GM-CSF has recently been implicated in as-yet unpublished work of researchers at the University of Melbourne. As part of the expanded relationship, new patent applications have been filed, which are intended to broaden the patent position of the anti-GM-CSF approach.

Theravance Announces New Employment Inducement Awards

Wed, 01 Jul 2009 20:30:00 EDT

SOUTH SAN FRANCISCO, CA--(Marketwire - July 1, 2009) - Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to three new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to facilitate the granting of equity awards to new employees. In accordance with Nasdaq rules, these grants were made under an equity incentive plan without stockholder approval. Nasdaq rules require a public announcement of equity awards to be made under this type of plan. Three employees were granted options to purchase an aggregate of 90,000 shares of the Company's common stock, which options vest over four years and expire in 10 years assuming continued employment. No officers received any award under this plan. The exercise price for the option shares granted

FDA Black Box Warning for Pfizer Smoking Cessation Drug Chantix(R); Cory Watson Crowder and DeGaris Charges Pfizer Knew of Potential Chantix Dangers

Wed, 01 Jul 2009 19:39:00 EDT

BIRMINGHAM, AL--(Marketwire - July 1, 2009) - The FDA has mandated a "Black Box Warning" requiring Pfizer Inc., manufacturer of Chantix�, to strengthen warnings about the health risks and dangers associated with using the drug. Chantix� (varenicline) is advertised as an aid to help people quit smoking. The order for a Boxed Warning comes on the heels of reports linking Chantix� to serious injuries and death. FDA officials noted, "These reports included those with a temporal relationship between the use of [Chantix] and suicidal events and the occurrence of suicidal ideation and suicidal behavior in patients with no history of psychiatric disease." In addition to requiring a stronger Boxed Warning, the FDA is requiring Pfizer to "develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms." The FDA Advisory also requires new "Black Box" warnings to be included on packages of smoking

Skystar Bio-Pharmaceutical Announces Exercise of Over-Allotment Purchase Option

Wed, 01 Jul 2009 19:32:00 EDT

XI'AN, CHINA--(Marketwire - July 1, 2009) - Skystar Bio-Pharmaceutical Co., Ltd. (NASDAQ: SKBI), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that Rodman & Renshaw, LLC exercised the over-allotment option to purchase an additional 210,000 shares of common stock, raising an additional $2.73 million in gross proceeds and bringing total gross proceeds of the offering to $20.90 million, prior to deducting underwriting discounts, commissions and offering expenses.

CryoPort Files 10K for Year Ended March 31, 2009

Wed, 01 Jul 2009 18:01:00 EDT

Company Announces Opening Its India Refurbishing and Staging Site

EnviroLogix Announces Receipt of DNA Development Award

Wed, 01 Jul 2009 14:03:00 EDT

PORTLAND, ME--(Marketwire - July 1, 2009) - Earlier in June, EnviroLogix was one of five Maine companies to receive a Maine Technology Institute "Development Award." Fourteen companies applied for competitive Development funds. The award, made by MTI's Board of Directors, provides for up to $500,000 in funding to selected recipients and requires at least a 1:1 dollar match by the winning company. EnviroLogix applied for and was awarded $499,727 and will match with $499,805.

Supplemented by this award, EnviroLogix will continue to improve and optimize isothermal amplification methods, exclusively licensed from Ionian Technologies Inc. (San Diego, CA) for agricultural, plant pathogen and veterinary markets. The NEAR (Nicking Enzyme Amplification Reaction) Assay permits the amplification of DNA and RNA in approximately 5-7 minutes, with sensitivity and specificity equal to or better than PCR methods. The amplification products can be detected by a variety of standard methods, incl

American Diabetes Association Names David M. Kendall, MD, as Organization's New Chief Scientific and Medical Officer

Wed, 01 Jul 2009 12:25:00 EDT

ALEXANDRIA, VA--(Marketwire - July 1, 2009) - The American Diabetes Association announced today that David M. Kendall, MD, has been named Chief Scientific and Medical Officer for the American Diabetes Association, effective September 21, 2009. Dr. Kendall is currently Medical Director and Chief of Clinical and Professional Services at the International Diabetes Center in Minneapolis, MN, and succeeds Richard A. Kahn, PhD, who retired from the Association on June 30, 2009.

As Chief Scientific and Medical Officer for the American Diabetes Association, Dr. Kendall will provide oversight for the Association's research grant program, certification programs, clinical guidelines, professional education programs, and general information resources.

Reimbursement Landscape Demands Health Outcomes Research Earlier in Development, Says Cutting Edge Information

Wed, 01 Jul 2009 10:15:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwire - July 1, 2009) - Stringent payer demands are causing companies to reprioritize health outcomes and cost-effectiveness data from post-launch and integrating them into clinical development, according to a newly released Cutting Edge Information study on payer relationship management.

The study "Securing Market Access: Reimbursement, Payer Relationships and Healthcare Reform" (http://www.cuttingedgeinfo.com/market-access) finds that, on average, cost-effectiveness studies cost $165,000; cost-benefit analysis studies, $27,000. Conducting pharmacoeconomic research in early development can result in significant cost-savings, helping to prevent delays to launch. It can also avoid Phase 4 studies, which can cost up to $175,000.

Genetic Immunity, InPlay: Company Completes Patient Enrollment in Italian Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine

Wed, 01 Jul 2009 10:05:00 EDT

BUDAPEST, HUNGARY--(Marketwire - July 1, 2009) - Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.

Genetic Immunity is pleased to announce completion of patient enrollment in the Company's Phase II randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load set point following analytical treatment interruption (ATI). This second Phase II study is conducted at the IRCCS Policlinico S.

BioElectronics Corp.'s Patented ActiPatch(R) Therapy and Allay(TM) Patches Are Safe and Effective Alternatives to Acetaminophen

Wed, 01 Jul 2009 10:00:00 EDT

Management and Leading Physicians Comment on FDA Panel Recommendation

MattsonJack Adds Indications to Epi Database

Wed, 01 Jul 2009 09:23:00 EDT

Pharma's Gold-Standard Epidemiology Data Set in G7 Countries and Emerging Markets of Brazil, Russia, India, and China

Cardioxyl Pharmaceuticals Initiates Phase I/IIa Study in Heart Failure

Wed, 01 Jul 2009 08:30:00 EDT

Study to Evaluate the Safety and Tolerability of Lead Candidate, CXL-1020, in the Treatment of Cardiovascular Disease

CNS Response Addresses "Notice of Special Meeting of Stockholders of CNS Response, Inc." Mailings

Wed, 01 Jul 2009 08:00:00 EDT

COSTA MESA, CA--(Marketwire - July 1, 2009) - CNS Response, Inc. (OTCBB: CNSO) (the "Company") is issuing this press release in order to provide its stockholders with information regarding one or more communications that they may have received in the mail captioned "Notice of Special Meeting of Stockholders of CNS Response, Inc." These communications, purporting to call a special meeting of Company stockholders, were neither authorized nor mailed to stockholders by the Company. Rather, the communications were mailed by the former Chief Executive Officer of the Company, Leonard Brandt, who was dismissed from that position by the Board of Directors on April 10, 2009. Mr. Brandt is attempting to call the meeting pursuant to the provisions of the bylaws of the Company that permit stockholders holding at least 1/4 of its outstanding shares to call a special meeting of stockholders.

Department of Defense Releases Further Funding to Cleveland BioLabs Under $8.8 Million Contract for Development Studies on Protectan CBLB502

Wed, 01 Jul 2009 08:00:00 EDT

BUFFALO, NY--(Marketwire - July 1, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Product Management Office (CBMS-MITS JPMO) of The Department of Defense (DoD) has exercised the contract option and released a second phase of funding under a contract calling for developmental studies valued at up to $8.8 million, awarded in April 2008.

Online Legal Steroids Announces HGH Factor: Non-Injectable Human Growth Hormone in Tablet Form

Wed, 01 Jul 2009 06:00:00 EDT

ST. PETERSBURG, FL--(Marketwire - July 1, 2009) - Online Legal Steroids, a leading online supplier of muscle enhancers, bodybuilding supplements and legal steroids products, has announced that a new product, HGH Factor, will be added to OnlineLegalSteroids.com.

HGH for injection is one of the most expensive drugs in the United States, with a cost that can range between $800 and $3,000 per month. HGH Factor is taken in tablet form with no needles and no doctor's prescription necessary. HGH Factor is about 80% cheaper than human growth hormone while still retaining all of the benefits.

Skystar Bio-Pharmaceutical Announces Pricing of Public Offering of Common Stock

Tue, 30 Jun 2009 21:00:00 EDT

XI'AN, CHINA--(Marketwire - June 30, 2009) - Skystar Bio-Pharmaceutical Co., Ltd. (NASDAQ: SKBI), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that it has priced its public offering of 1,400,000 shares of common stock. Skystar has granted the representative of the underwriters a 45-day option to purchase up to an additional 210,000 shares of common stock. The shares were offered to the public at $12.98 per share. The offering is expected to settle and close on July 7, 2009, subject to customary closing conditions. Net proceeds from the offering are expected to be used for the completion of a new vaccine facility; the construction of a new production facility for micro-organisms and feed additives; acquisitions of other companies in the veterinary healthcare industry; and working capital and general corporate purposes, including researc

Statement From the Consumer Healthcare Products Association on Today's Joint FDA Advisory Committee Recommendations on Over-the-Counter Medicines Containing Acetaminophen

Tue, 30 Jun 2009 19:00:00 EDT

WASHINGTON, DC--(Marketwire - June 30, 2009) - Following is a statement by Linda A. Suydam, D.P.A., president of the Consumer Healthcare Products Association (CHPA), regarding the recommendations issued today by the U.S. Food and Drug Administration's Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee. The joint committee addressed the use of over-the-counter (OTC) and prescription (Rx) drugs containing acetaminophen.

Savaria Corporation Issuer Bid

Tue, 30 Jun 2009 17:09:00 EDT

LAVAL, QUEBEC--(Marketwire - June 30, 2009) - Savaria Corporation ("Savaria" or the "Corporation") (TSX:SIS), the second largest company in the accessibility industry in North America, today announced that it has commenced with the issuer bid for up to 4,000,000 common shares (14.8% of the issued and outstanding common shares) at a price of C$0.90 per share with a 35 day deposit period expiring on August 4, 2009 ("Issuer Bid'). Savaria currently has 27,061,014 common shares issued and outstanding.

The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635

Tue, 30 Jun 2009 17:00:00 EDT

PARSIPPANY, NJ--(Marketwire - June 30, 2009) - The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire due to additional hiring in connection with its global expansion.

The inducement stock options covers 1,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent of these options will vest on the date one year from the optionee's hire date, the remainder will vest in monthly increments during the following 36 months (in all cases subject to the terms and conditions of the Company's 2009 Equity Inducement Plan).

UCB and Biogen Idec discontinue Phase II clinical trial of CDP323

Tue, 30 Jun 2009 16:39:00 EDT

BRUSSELS, BELGIUM--(Marketwire - June 30, 2009) -

Preliminary interim efficacy analysis showed no clinically relevant benefit for patients

Brussels (Belgium), 30 June 2009 at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted.

HearAtLast Establishes Advisory Board to Manage Growth Opportunities and Appoints First Two Members

Tue, 30 Jun 2009 16:19:00 EDT

MISSISSAUGA, ON--(Marketwire - June 30, 2009) - HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced today the formation of its advisory board with the appointment of Louie Mele, consultant and former CEO of McDonald's Canada, and Gora Ganguli, President & CEO of VitaSound Audio, Inc.

Matthew Sacco, CEO of HearAtLast, commented, "The board was created to add depth to the management team and gather knowledge from experienced business professionals and select individuals within the industry. This will increase HearAtLast's capabilities while exploring new opportunities to enhance shareholder value, business development and growth."

Myriad Genetics Announces Preliminary Revenue Results for Fiscal 2009 Fourth Quarter, Full Year

Tue, 30 Jun 2009 16:05:00 EDT

SALT LAKE CITY, UT--(Marketwire - June 30, 2009) - Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that, based on preliminary estimates, it anticipates reporting total molecular diagnostic revenue, which represents the bulk of the Company's revenue, of approximately $86 million for the fiscal 2009 fourth quarter ending June 30, 2009. The Company continues to believe that revenue for the fiscal 2009 fourth quarter is being impacted by the current economic recession, which is driving increasing unemployment levels resulting in the loss of insurance coverage and patients delaying or cancelling doctor visits.

Ambrilia Biopharma Inc.: Annual and Special Meeting of Shareholders

Tue, 30 Jun 2009 15:01:00 EDT

ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS

Ambrilia Biopharma inc. : Assembl�e annuelle et extraordinaire des actionnaires

Tue, 30 Jun 2009 15:01:00 EDT

Attention Directeurs des rubriques affaires/Finance/Sant�

The Multiple Sclerosis Association of America's Interactive Video Series Wins Prestigious Business Award

Tue, 30 Jun 2009 14:32:00 EDT

CHERRY HILL, NJ--(Marketwire - June 30, 2009) - The Multiple Sclerosis Association of America's (MSAA) educational web video series, "A Closer Look," recently won the highly acclaimed Stevie Award in the category of Interactive Multimedia/Public Information. This video series has become the cornerstone of MSAA's educational video initiative, MSi (Multiple Sclerosis information), which includes 16 on-demand video programs. Program topics cover medical, family, lifestyle, disability, and legal issues. Individuals with MS or those interested in learning about MS may access these award-winning videos by visiting http://www.msassociation.org/programs/videos/

VIVALIS RAISES ITS 2009 COMMERCIAL TARGETS

Tue, 30 Jun 2009 11:52:00 EDT

NANTES, FRANCE--(Marketwire - June 30, 2009) - NEW RESEARCH LICENSE AGREEMENT FOR ANTIBODIES

2009 COMMERCIAL TARGETS RAISED: 10 NEW LICENSE AGREEMENTS

Nantes (France) - 30 June 2009 - VIVALIS (NYSE Euronext: VLS) announced today the signature of a new research agreement with a company whose name remains undisclosed for the production of monoclonal antibodies on its EB66� cell line platform.

2009 commercial targets exceeded

Since January 1, 2009, VIVALIS has signed seven new commercial licenses, already outperforming the full-year commercial target announced January 13 of this year.

2009 marque le 40e anniversaire de la libert� de choix et de l'�mancipation sexuelle des Canadiennes

Tue, 30 Jun 2009 10:00:00 EDT

En juin 1969, le gouvernement canadien l�galisait la contraception.

Ambient ID Unveils LabTrack(TM) Diagnostic Specimen Tracking Solution

Tue, 30 Jun 2009 10:00:00 EDT

Proven Automatic Identification and Business Information Management Technologies Improve Diagnostic Laboratory Operations, Reduce Testing Costs

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

Tue, 30 Jun 2009 09:51:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwire - June 30, 2009) - Biological drugs are the big winners in the market for autoimmune disorders. According to "Autoimmune Market Forecast to 2014," the latest therapeutic market forecast from Cutting Edge Information, 11 of 14 drugs projected to reach blockbuster status are biologics. In fact, sales of biologics marketed for at least one autoimmune disorder topped $29 billion in 2008. In the same year, small molecules earned only $9 billion.

With projected biologics sales projected to hit $55 billion in 2014, nearly all of the major pharmaceutical companies have acquired or partnered with biotechnology firms to develop biologics with potential in this area.

Over 25 New Features in Geneious(TM) 4.7

Tue, 30 Jun 2009 09:30:00 EDT

AUCKLAND, NEW ZEALAND--(Marketwire - June 30, 2009) - GeneiousT 4.7 boasts a new ultra-fast sequence assembler that allows users to assemble sequences generated from the Sanger and 454 high-throughput methods to a reference genome. GeneiousT version 4.7 is the first release in a three-phase release-strategy that will provide increasing support for next-generation high-throughput sequence data with SOLiD and Genome Analyzer II (Solexa) support to follow in the next release all in the most user-friendly environment available.

BioSpace and IBC Life Sciences Announce Career Fair Alliances

Tue, 30 Jun 2009 09:00:00 EDT

Drug Discovery & Development Week, Boston, MA; BioProcess International(TM) Conference & Exhibition, Raleigh, NC

Vigilos(R) Releases Version 5.2 of BrightSite(R) Technology

Tue, 30 Jun 2009 09:00:00 EDT

SEATTLE, WA--(Marketwire - June 30, 2009) - Vigilos, Inc. released version 5.2 of its BrightSite� technology today, with benefits applicable to a variety of process-oriented industries.

The BrightSite� product addresses issues that range from connecting a food processing company's production activities to its existing security technologies, allowing them to make measurable improvements in labor optimization, manufacturing, employee welfare, premises security, and safety, to securing thousands of critical sites for the Federal Government.

Transfer Technology International's Board of Directors Appoints Highly Decorated Retired 4-Star Admiral to Vice-Chairman Position

Tue, 30 Jun 2009 09:00:00 EDT

TAMPA, FL--(Marketwire - June 30, 2009) - (PINKSHEETS: TTIN) Today the company is announcing the appointment of retired four star admiral Henry G. "Harry" Ulrich III to the position of Vice-Chairman of its Board of Directors. In a unanimous in-favor vote recently the current Board has appointed Mr. Ulrich to fulfill the capacity of its Vice-Chairman position as a non-executive of its financial Board of Directors which brings the total board members to five.

Medicare Part D Texas Drug Plan Beneficial to Senior Citizens

Tue, 30 Jun 2009 09:00:00 EDT

Medical Reimbursement Resource Assists Seniors in Selecting the Best Plan

Study Finds Edwards Lifesciences' Port Access System Facilitates Improved Outcomes Compared to Sternotomy

Tue, 30 Jun 2009 09:00:00 EDT

BERLIN--(Marketwire - June 30, 2009) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves, announced that new research demonstrates that using its minimally invasive PORT ACCESS System in mitral valve surgery significantly decreases the length of stay in hospitals and intensive care units (ICU), and improves other outcomes when compared to conventional sternotomy (an incision the length of the chest). Results were presented today at the Society for Heart Valve Disease 5th Biennial Meeting in Berlin.

Smith & Nephew - Total Voting Rights

Tue, 30 Jun 2009 08:37:00 EDT

London, UK--(Marketwire - June 30, 2009) -



Smith & Nephew plc - Voting Rights and Capital


30 June 2009


In conformity with Rule 5.6.1 of the FSA's Disclosure
and Transparency Rules, we notify the market that as at 30 June 2009:


Smith & Nephew plc's issued share capital with voting rights consists
of 884,093,133 ordinary shares of US20c each.  


65,984,911 ordinary shares are held in treasury, and are not included
in the above figure.


884,093,133 ordinary shares may be used by shareholders for calculating
if they are required to notify their interest in, or change to their
interest in, the Company under the FSA's Disclosure and Transparency
Rules.



Susan Henderson

Company Secretary

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

AspenBio Pharma Files 510(k) Notification With FDA for AppyScore(TM) Test

Tue, 30 Jun 2009 08:30:00 EDT

Filing Advances AppyScore(TM) Test as the World's First Blood-Based Test to Aid in the Diagnosis of Human Appendicitis

Green Planet Delivers Strong First Quarter 2009 Results

Tue, 30 Jun 2009 07:00:00 EDT

MIAMI, FL--(Marketwire - June 30, 2009) - Green Planet Bioengineering CO., LTD. (OTCBB: GPLB) ("Green Planet" or the "Company"), a leading bioengineering enterprise dedicated to creating high quality chemical intermediates and innovative downstream health products using green processes, reports record first quarter 2009 results.

First quarter 2009 revenue was up 5% to $2,297,621 compared to $2,192,799 for the same period last year. EBITDA (defined as earnings before interest, taxes, depreciation and amortization) was $1,211,679 as compared to $1,239,300 for the same period last year. Operating Income was $1,140,223 compared to $1,130,911 for the same period last year. Net Profit remained relatively flat at $842,725 compared to $862,203 for the same period last year due to an increase in the effective tax rate originating from non taxable subsidy income in 2008.

SciClone Pharmaceuticals, Inc. Added to Russell 3000(R) Index

Tue, 30 Jun 2009 06:00:00 EDT

FOSTER CITY, CA--(Marketwire - June 30, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has been added to the Russell 2000� and Russell 3000 Indexes.

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies and is a combination of the Russell 1000� and Russell 2000 Indexes. The Russell 2000 Index is a subset of the Russell 3000 Index, representing approximately 10% of the total market capitalization of that index.

BioCentric Energy Holdings to File Additional Provisional Patent to Enhance Efficency & Capital Reduction Cost of Algae Pro Photobioreactor System

Tue, 30 Jun 2009 06:00:00 EDT

SAN JUAN CAPISTRANO, CA--(Marketwire - June 30, 2009) - BioCentric Energy Holdings, Inc.(PINKSHEETS: BEHL) provides corporate update for shareholders:

Dennis Fisher, CEO, BioCentric Energy Holdings, Inc. today announced that the company decided to move forward in filing an additional provisional patent to enhance the Algae Pro closed loop Photobioreactor system. Specifically, the company's unique 180 degree "turn" has been redesigned again after the wet test to enhance the efficiency and significantly reduce capital costs.

Number of shares and votes in Active Biotech

Tue, 30 Jun 2009 02:30:00 EDT

LUND, SWEDEN--(Marketwire - June 30, 2009) - The number of shares and votes in Active Biotech has changed as a consequence of the recently completed rights issue with pre-emptive rights for the shareholders.

Today, the last trading day of the month, there are in total 64,052,238 shares and votes in Active Biotech.

Lund, June 30, 2009
Active Biotech AB (publ)


For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com

Appointment of Dr. Philip M. Toleikis to the Sernova Board of Directors

Mon, 29 Jun 2009 17:45:00 EDT

LONDON, ONTARIO--(Marketwire - June 29, 2009) - Sernova Corp. (TSX VENTURE:SVA) Dr. George Adams, Chairman of the Board of Directors of Sernova Corp. is pleased to announce the appointment of Dr. Philip Toleikis to the Corporation's Board of Directors. Dr. Toleikis was previously appointed as President and Chief Executive Officer of Sernova on April 28, 2009. In making the appointment, Dr. Adams said "Dr. Toleikis is now a key element in Sernova's future success, and it is important going forward to utilize his extensive scientific and business knowledge and expertise at the Board level. On behalf of the Corporation's shareholders and the other Board members, I would like to welcome him to the Board."

Warnex's Medical Laboratories Division Obtains ISO 15189 Accreditation

Mon, 29 Jun 2009 17:00:00 EDT

LAVAL, QUEBEC--(Marketwire - June 29, 2009) - Warnex Inc. (TSX:WNX) announced today that its Medical Laboratories division has obtained ISO 15189:2007 accreditation by the Standards Council of Canada (SCC). This accreditation is an international standard for quality management systems for medical testing laboratories. Warnex Medical Laboratories is only the second private laboratory in Canada to obtain this accreditation. "We are pleased and proud to have received this second ISO accreditation for our Medical Laboratories division, demonstrating once again our commitment to the highest standards of quality," said Mark Busgang, President and CEO of Warnex. "We place great importance not only on the quality of our specialized lab services, but also on their continuous improvement. To this end, our dedicated staff worked diligently to achieve ISO 15189 accreditation and continues to expend efforts towards expanding our portfolio of specialized medical testing services."

Warnex laboratoires m�dicaux obtient l'accr�ditation ISO 15189

Mon, 29 Jun 2009 17:00:00 EDT

LAVAL, QUEBEC--(Marketwire - 29 juin 2009) - Warnex inc. (TSX:WNX) a annonc� aujourd'hui que sa division de Laboratoires m�dicaux a obtenu l'accr�ditation ISO 15189:2007 par le Conseil canadien des normes (CCN). Cette accr�ditation est une norme internationale pour les syst�mes de gestion de la qualit� des laboratoires d'analyse m�dicale. Warnex laboratoires m�dicaux est seulement le deuxi�me laboratoire priv� au Canada � obtenir cette accr�ditation. "Nous sommes heureux et fiers d'avoir obtenu cette deuxi�me accr�ditation ISO pour notre division de laboratoires m�dicaux, d�montrant encore une fois notre engagement aux plus hauts standards de qualit�" a affirm� Mark Busgang, pr�sident et chef de la direction de Warnex. "Nous attachons une grande importance non seulement � la qualit� de nos services de laboratoire sp�cialis�s, mais �galement sur leur am�lioration continue. A cet effet, notre personnel d�vou� a travaill� diligemment pour obtenir l'accr�ditation ISO 15189 et continue �

TapImmune Announces Corporate Restructuring

Mon, 29 Jun 2009 17:00:00 EDT

BELLEVUE, WA--(Marketwire - June 29, 2009) - TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the appointment of Dr. Glynn Wilson as TapImmune's new Executive Chairman as part of an overall corporate restructuring plan.

Dr. Wilson succeeds Alan Lindsay whom TapImmune Inc. thanks for his service and contributions to TapImmune.

HearAtLast Exclusive Distributor of World's Smallest Standard Fitted CIC Hearing Aid

Mon, 29 Jun 2009 16:50:00 EDT

MISSISSAUGA, ON--(Marketwire - June 29, 2009) - HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), a leading provider of hearing solutions through their Hearing Stores, is pleased to announce its exclusive distribution agreement with ExSilent for Canada. With this new virtually invisible device touted as the "World's Smallest standard fitting CIC," we are confident that this will reach the untapped first-time buyer and more youthful hearing impaired market.

Chembio Presenting DPP(R) Syphilis at ISSTDR Congress

Mon, 29 Jun 2009 16:27:00 EDT

DPP(R) HIV, Hepatitis-C & HIV-Hepatitis Combination Oral Fluid Tests in CDC Study

BrightTALK Hosts eHealth Summit

Mon, 29 Jun 2009 12:30:00 EDT

Interact With eHealth Experts Live on BrightTALK

ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R

Mon, 29 Jun 2009 12:08:00 EDT

GHENT, BELGIUM--(Marketwire - June 29, 2009) -

GHENT, Belgium, 29 June 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies�, a novel class of antibody-derived therapeutic proteins, today announced that it has advanced ALX-0061, a new Nanobody�-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.

ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target.

OctoPlus' Licensee Biolex Completes Patient Enrollment in Phase IIb Study With Locteron

Mon, 29 Jun 2009 11:30:00 EDT

LEIDEN, THE NETHERLANDS--(Marketwire - June 29, 2009) - OctoPlus N.V. ("OctoPlus") (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron�, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008.

Amarillo Biosciences and CytoPharm Announce Start of Enrollment for Hepatitis C Study in Taiwan

Mon, 29 Jun 2009 11:09:00 EDT

AMARILLO, TX--(Marketwire - June 29, 2009) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) and CytoPharm, Inc. today jointly announced the start of enrollment for a study of ABI's oral interferon-alpha lozenges for chronic hepatitis C virus infection. The aim of the trial is to reduce the virologic relapse rate for those patients who have completed the standard combination therapy, which consists of high dose injectable interferon-alpha and Ribavirin. Although most patients respond to the standard therapy, up to 50% of those with certain "high-risk" viral genotypes relapse after treatment.

OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron

Mon, 29 Jun 2009 10:49:00 EDT

LEIDEN, NETHERLANDS--(Marketwire - June 29, 2009) - OctoPlus N.V. ("OctoPlus") (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron�, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008.

Ondine Completes $0.9 Million Private Placement

Mon, 29 Jun 2009 09:03:00 EDT

Placements for $2.7 Million Completed in the Past Month

Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2b Trial of Locteron(R) in Chronic Hepatitis C

Mon, 29 Jun 2009 09:00:00 EDT

PITTSBORO, NC--(Marketwire - June 29, 2009) - Biolex Therapeutics, Inc. announced today that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron� for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the side effects, including flu-like symptoms, associated with pegylated interferons, the current standard of care.

TearLab Corporation Announces Change in Company Leadership

Mon, 29 Jun 2009 08:45:00 EDT

SAN DIEGO, CALIFORNIA--(Marketwire - June 29, 2009) - OccuLogix, Inc. dba TearLab Corporation (NASDAQ:TEAR)(TSX:TLB) today announced that its Chief Executive Officer, Eric Donsky, is leaving the company to pursue other opportunities effective immediately. The Company's Board of Directors has appointed its Chairman, Elias Vamvakas, to serve as Interim Chief Executive Officer until a permanent replacement for Mr. Donsky can be found. "TearLab Corporation has achieved a number of important milestones in recent months, not the least of which was FDA 510(k) clearance of our award-winning TearLab(TM) Osmolarity System," commented Company director, Donald Rindell. "On behalf of the Board, I would like to take this opportunity to thank Eric for his dedication and many valuable contributions. Eric founded OcuSense with Dr. Benjamin Sullivan in 2003 and remained CEO through its merger with Occulogix in October 2008."

Adeona Announces Appointment of Max Lyon as Chief Executive Officer and President

Mon, 29 Jun 2009 08:44:00 EDT

ANN ARBOR, MI--(Marketwire - June 29, 2009) - Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a specialty pharmaceutical company dedicated to the awareness, prevention and treatment of subclinical zinc deficiency and chronic copper toxicity in the mature adult population, today announced that it has appointed Max Lyon as Chief Executive Officer and President of Adeona.

Mr. Lyon has been CEO/President of six successful medical diagnostic and therapeutic companies, five of which he co-founded, including BioControl Systems, Bainbridge Sciences (Bard Diagnostics), MediQuest Therapeutics, NexCura, Confirma and CG Therapeutics. He co-founded and led the acquisition of Bainbridge Sciences by C.R. Bard and continued as the President of Bard Diagnostics, and a senior executive team member of C.R. Bard, for four years. He also served as Senior Vice President of Administration at Genetic Systems and was a co-founder and Dire

Paladin Acquires Products From Wyeth

Mon, 29 Jun 2009 08:00:00 EDT

MONTREAL, QUEBEC--(Marketwire - June 29, 2009) - Paladin Labs Inc. (TSX:PLB) announced today that it has entered into an agreement with Wyeth to acquire a bundle of products currently marketed in Canada by Wyeth that includes Anacin(R) (acetylsalicylic acid) and Anbesol(R) (benzocaine). Financial terms of the agreement were not disclosed. Canadian net sales of the portfolio of products amounted to approximately $4 million for calendar 2008. The acquired products complement Paladin's growing OTC portfolio and represent the first significant deployment of funds since the company's recent financing that contributed gross proceeds of approximately $58.7 million.

Paladin acquiert des produits de Wyeth

Mon, 29 Jun 2009 08:00:00 EDT

MONTREAL, QUEBEC--(Marketwire - 29 juin 2009) - Laboratoires Paladin inc. (TSX:PLB) a annonc� aujourd'hui la conclusion d'un accord avec Wyeth portant sur l'achat d'un groupe de produits actuellement vendus au Canada par Wyeth, qui comprend Anacin(R) (acide ac�tylsalicylique) et Anbesol(R) (benzoca�ne). Les modalit�s financi�res de l'accord n'ont pas �t� divulgu�es. Le chiffre d'affaires canadien net du portefeuille de produits s'�levait � environ 4 millions de dollars pour l'ann�e 2008. Les produits achet�s compl�mentant le portefeuille croissant de produits en vente libre de Paladin, et constituent la premi�re sortie de fonds importante de la Soci�t� depuis son r�cent financement qui a contribu� pour un produit brut d'environ 58,7 millions de dollars.

Prevent Blindness America Approves PediaVision Assessment Solution

Mon, 29 Jun 2009 08:00:00 EDT

Supported by Studies in Journal of American Academy of Pediatric Ophthalmology, and Binocular Vision and Strabismus Quarterly; PediaVision Screening Device Passes Rigorous Tests Based Upon ATS, VIP, or AAP Protocol

Micro Imaging Technology Signs Partner to Expand Sales and Manufacturing to Asia

Mon, 29 Jun 2009 07:30:00 EDT

SAN CLEMENTE, CA--(Marketwire - June 29, 2009) - Micro Imaging Technology, Inc. (OTCBB: MMTC) announced that it has entered into a strategic business development relationship with OPH Ltd. Hong Kong who will be instrumental in securing a manufacturing partner for the Company in Asia. In addition, OPH will develop this market for the MIT 1000 Rapid Microbial Identification System through its distribution channels by working closely with existing Micro Imaging Technology (MIT) distributors and jointly with MIT to identify and select other strategic partners to expand the Company's MIT 1000 business in Asia.

Accelrys Releases New Modeling and Simulation Software for Life Science Researchers With Discovery Studio(R) 2.5

Mon, 29 Jun 2009 07:00:00 EDT

Innovative Science in the Areas of Small Molecule Modeling, Fragment-Based Design, Transmembrane Proteins, and Antibody Modeling Sets New Standard for Life Science Research and Development

Lorus Announces Publication of a Novel Analytical Method Confirming the Pharmacological Action of Its Anticancer Drug LOR-2040

Mon, 29 Jun 2009 07:00:00 EDT

- Demonstrated in leukemia cell lines and bone marrow samples from an AML patient

Stantum and Sitronix Team to Meet Demand for Cost-Effective, High-Performance Multi-Touch in Consumer and Mobile Applications

Mon, 29 Jun 2009 03:01:00 EDT

BORDEAUX, FRANCE--(Marketwire - June 29, 2009) - Stantum (www.stantum.com), the pioneer developer of multi-touch technology, and Sitronix, a global leader of LCD driver and SoC IC design, announced a partnership to provide voltage matrix multi-touch single-chip solutions. Under a licensing agreement, Sitronix will integrate Stantum's patented multi-touch screen technology into its own products and supply high-performance multi-touch controllers for consumer electronics and mobile applications.

Stantum y Sitronix se unen para satisfacer la demanda de tecnolog�a multit�ctil de alto rendimiento y rentable para productos de consumo y aplicaciones m�viles

Mon, 29 Jun 2009 03:01:00 EDT

BORDEAUX, FRANCIA--(Marketwire - June 29, 2009) - Stantum (www.stantum.com), el desarrollador pionero de tecnolog�a multit�ctil y Sitronix, un l�der global de unidades LCD y dise�o SoC IC, anunciaron una asociaci�n para ofrecer soluciones de matriz de voltaje multit�ctil con un solo chip. Bajo un acuerdo de licenciamiento, Sitronix integrar� la tecnolog�a patentada de pantalla multit�ctil de Stantum a sus propios productos y proveer� controladores multit�ctiles de alto rendimiento para productos electr�nicos de consumo y aplicaciones m�viles.

Stantum e Sitronix se unem para atender a demanda de multi-toque de alta performance e de custo eficaz para aplicativos de consumo e m�veis

Mon, 29 Jun 2009 03:01:00 EDT

BORDEAUX, FRANCE--(Marketwire - June 29, 2009) - A Stantum (www.stantum.com), pioneira no desenvolvimento de tecnologias de multi-toque, e a Sitronix, l�der global de LCD driver e design SoC IC, anunciou a forma��o de uma parceria para o fornecimento de solu��es de chip �nico de multi-toque com matriz de voltagem. Com este acordo de licenciamento, a Sitronix integrar� a tecnologia de tela de multi-toque patenteada da Stantum nos seus produtos e fornecer� controles multi-toque de alta performance para aplicativos eletr�nicos e m�veis de consumo.

OctoPlus appoints Susan Swarte as Chief Financial Officer

Mon, 29 Jun 2009 02:10:00 EDT

LEIDEN, THE NETHERLANDS--(Marketwire - June 29, 2009) - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer. At the next general meeting of shareholders the Board of Supervisory Directors will propose to appoint Mrs. Swarte as member of the Executive Board for a period of four years. After approval of the shareholders, OctoPlus' Executive Board will consist of Chief Executive Officer Simon Sturge, Chief Financial Officer Susan Swarte, Chief Scientific Officer Joost Holthuis and Chief Business Officer Gerben Moolhuizen.

UCB brings Neupro(R) back to all patients in Europe

Mon, 29 Jun 2009 02:07:00 EDT

BRUSSELS, BELGIUM--(Marketwire - June 29, 2009) -

  * European Commission lifts the treatment restrictions for Neupro�
  * Neupro� can be prescribed for all patients in accordance with the
    approved indications

       * Neupro� available again to all patients with Parkinson's
         disease
       * Neupro� newly available to adult patients with moderate to
         severe Restless Legs Syndrome

Brussels (Belgium), 29 June 2009 - press release, regulated information - UCB announced today that Neupro� (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. This follows the decision of the European Commission to lift treatment restrictions on Neupro� in line with the recommendation of the European Medicines Agency (EMEA), issued on 29 May 20

OctoPlus appoints Susan Swarte as Chief Financial Officer

Mon, 29 Jun 2009 01:39:00 EDT

LEIDEN, NETHERLANDS--(Marketwire - June 29, 2009) -

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer. At the next general meeting of shareholders the Board of Supervisory Directors will propose to appoint Mrs. Swarte as member of the Executive Board for a period of four years. After approval of the shareholders, OctoPlus' Executive Board will consist of Chief Executive Officer Simon Sturge, Chief Financial Officer Susan Swarte, Chief Scientific Officer Joost Holthuis and Chief Business Officer Gerben Moolhuizen.

MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program

Mon, 29 Jun 2009 01:30:00 EDT

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - June 29, 2009) -

Seventh HuCAL Antibody to Enter Clinical Trials

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it will receive a milestone payment from Centocor Ortho Biotech Inc. (formerly known as: Centocor, Inc.) in connection with the initiation of a Phase 1 clinical trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.

"The advancement of a new HuCAL antibody into human clinical trials is an important step forward for MorphoSys," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Progress in the development of innovative biopharmaceutical agents by our partners is a key driver of our company's growth."

Hypoglycemia Increases Mortality Risk, Lengthens Hospital Stay for Diabetes Patients -- Even Outside the ICU

Mon, 29 Jun 2009 00:01:00 EDT

ALEXANDRIA, VA--(Marketwire - June 29, 2009) - Diabetes patients who are hospitalized for non-critical illnesses, and develop hypoglycemia while hospitalized, are likely to remain hospitalized longer and face greater risk of mortality both during and after hospitalization, according to a study published in the July issue of Diabetes Care.

This retrospective cohort study of more than 4,300 admissions, by researchers at Boston's Brigham and Women's Hospital, was the first to examine mortality risks for hospitalized diabetes patients outside a critical care setting. Previous research found an association between hypoglycemia in ICU patients and an increased risk of morality, seizures and coma.

WEX Reports Year End Financial Results

Fri, 26 Jun 2009 19:47:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 26, 2009) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) reported major events and financial results for the fiscal year ended March 31, 2009. All amounts, unless specified otherwise, are in Canadian dollars. Major Events - In April 2008, the Company announced the enrolment and dosing of the first patient in a Canadian Phase III clinical trial of TTX in cancer-related pain (TEC-006). This multi-centre, randomized, double-blind, and placebo-controlled trial will include approximately 120 patients with moderate to severe cancer-related pain.

Statement From the American Diabetes Association Related to Studies Published in Diabetelogia Suggesting Possible Link Between Insulin Glargine and Cancer

Fri, 26 Jun 2009 16:45:00 EDT

Research Conflicting and Inconclusive; Patients Should Not Stop Using Insulin and Should Talk to Their Doctor